TLSI | TriSalus Life Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.88 - 5.04
52 Week Range	3.50 - 10.42
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	35,820
Average Volume	37,222
Shares Outstanding	30,493,100
Market Cap	149,263,725
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2021-02-08

Valuation
Profitability
Growth
Health
P/E Ratio	-2.55
Forward P/E Ratio	N/A
EPS	-1.92
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	107
Country	USA
Website	TLSI

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

*Chart delayed

Analyzing fundamentals for TLSI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see TLSI Fundamentals page.

Watching at TLSI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TLSI Technicals page.